CCR3 and myeloid sarcoma: CD52 (Approved for MS. Reduces accumulation of disability (≥1.0 point on EDSS) reduced by 66%, relapse rate by 72%, and by 55%. Reduces CCR3, CCR4, CCR5, CCR6, CXCR3, CXCL10, and CCL20.